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Resequencing analysis of five Mendelian
genes and the top genes from genome-
wide association studies in Parkinson’s
Disease
Bruno A. Benitez1*, Albert A. Davis2, Sheng Chih Jin3, Laura Ibanez3, Sara Ortega-Cubero4,5, Pau Pastor5,6,
Jiyoon Choi3, Breanna Cooper3, Joel S. Perlmutter2,7,8 and Carlos Cruchaga3,8
Abstract
Background: Most sequencing studies in Parkinson’s disease (PD) have focused on either a particular gene, primarily
in familial and early onset PD samples, or on screening single variants in sporadic PD cases. To date, there is no
systematic study that sequences the most common PD causing genes with Mendelian inheritance [α-synuclein (SNCA),
leucine-rich repeat kinase 2 (LRRK2), PARKIN, PTEN-induced putative kinase 1 (PINK1) and DJ-1 (Daisuke-Junko-1)] and
susceptibility genes [glucocerebrosidase beta acid (GBA) and microtubule-associated protein tau (MAPT)] identified
through genome-wide association studies (GWAS) in a European-American case-control sample (n=815).
Results: Disease-causing variants in the SNCA, LRRK2 and PARK2 genes were found in 2 % of PD patients. The LRRK2,
p.G2019S mutation was found in 0.6 % of sporadic PD and 4.8 % of familial PD cases. Gene-based analysis suggests
that additional variants in the LRRK2 gene also contribute to PD risk. The SNCA duplication was found in 0.8 %
of familial PD patients. Novel variants were found in 0.8 % of PD cases and 0.6 % of controls. Heterozygous
Gaucher disease-causing mutations in the GBA gene were found in 7.1 % of PD patients. Here, we established that
the GBA variant (p.T408M) is associated with PD risk and age at onset. Additionally, gene-based and single-variant
analyses demostrated that GBA gene variants (p.L483P, p.R83C, p.N409S, p.H294Q and p.E365K) increase PD risk.
Conclusions: Our data suggest that the impact of additional untested coding variants in the GBA and LRRK2 genes is
higher than previously estimated. Our data also provide compelling evidence of the existence of additional untested
variants in the primary Mendelian and PD GWAS genes that contribute to the genetic etiology of sporadic PD.
Keywords: Parkinson’s, Association study, SNCA, LRRK2, PARKIN, PINK1, DJ-1, MAPT, GBA rare variants, gene-based analysis
Background
PD is the second most common neurodegenerative
disorder after Alzheimer’s disease (AD) [1]. By the year
2030, the prevalence of PD is projected to be between
8.7 and 9.3 million [1]. Genetic studies in PD have pro-
vided valuable insights into the underlying pathogenic
mechanisms [2], leading to the development of animal
models for investigation of disease mechanisms and
identification of novel therapeutic targets [3]. Initial
studies of multiplex families with PD found concordance
rates of 75 % in monozygotic twins, 22 % in dizygotic
twins [5], and an increased relative risk of PD of 2.9 (95
% CI 2.2–3.8) for those with an affected first-degree rela-
tive [6]. These findings indicate that the genetic eti-
ology of PD does not fit a simple genetic model [5].
GWAS of PD have identified variants at 20 loci influen-
cing PD risk [2, 4, 7–9], with population-specific differ-
ences [10, 11]. The currently identified genetic factors
explain only 6–7 % of the phenotypic variability associ-
ated with PD [12], and the most prevalent GWA sig-
nals account for only 3–5 % of PD genetic variance in
individuals of European ancestry [12]. These results
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provide unequivocal, compelling evidence for the exist-
ence of undiscovered genetic factors that contribute to the
etiology of PD. Both candidate gene association studies
and GWAS repeatedly validate that the most statistically
significant signals associated with PD are common vari-
ants located close to SNCA, LRRK2, MAPT genes and low
frequency coding variants in the GBA gene [2, 4, 7, 10,
13–16].
Non-coding variants are the most significant single
nucleotide polymorphisms (SNPs) identified near the
MAPT and SNCA genes by GWAS [4]. To date, the
functional variants driving such associations are un-
known. We hypothesize that low frequency or rare
coding variants can be identified by re-sequencing the
MAPT and SNCA genes. In addition, deep-sequencing
LRRK2 and GBA genes can not only identify additional
untested coding risk variants but also protective alleles,
as previously reported in these genes [17].
Highly penetrant mutations in the SNCA and LRRK2
genes are found in families with autosomal dominant
inheritance, whereas autosomal recessive families with a
typical PD phenotype carry mutations in the PARK2/
PARKIN, PARK6/PINK1 and PARK7/DJ-1 genes [18].
Most genetic studies in PD have focused on sequencing
a particular Mendelian gene in familial or early onset
PD, or have directly screened few variants in sporadic
PD cases in small samples [18]. A systematic study that
sequences all of these genes (SNCA, LRRK2, PARK2,
PINK1 and PARK7) in a large PD dataset has not been
reported in European Americans [19, 20]. Thus, we used
next-generation sequencing technology to re-sequence
five Mendelian and the top GWAS susceptibility PD
genes in a well-characterized case–control European
American dataset (478 cases and 337 healthy controls) to
identify both risk and protective low frequency or rare
variants for PD.
Results
We performed pooled DNA-targeted deep-sequencing
of the protein-coding regions of 7 genes, including 5
genes previously reported to most frequently cause fa-
milial forms of PD (SNCA, LRRK2, DJ-1, PARK2 and
PINK1) and 2 genes that have significant associations in
GWAS with sporadic PD (GBA and MAPT genes) in
478 PD patients and 337 healthy individuals of
European-American descent from the Washington Uni-
versity in Saint Louis Movement Disorder Clinic (Table 1)
[15, 21]. This cohort contains 83 % late-onset PD (LOPD)
and 74 % sporadic PD cases.
Rare variants in a European American case-control
sample
We validated missense and splice-affecting variants with
a predicted minor allele frequency (MAF) <5 %. In this
European-American descent sample, a total of 47 low-
frequency (0.5–5 %) and rare (<0.5 %) non-synonymous
coding variants were validated. 36.2 % (17/47) of the var-
iants are found in LRRK2, 21.2 % (10/47) in GBA, 17 %
(8/47) in PARK2, 14.9 % (7/47) in PINK-1, 8.5 % (4/47)
in MAPT and 2.1 % (1/47) in DJ-1 (Table 2). 70 % of
these variants are either singletons (24/47) or doubletons
(9/47).
Novel variants
8.5 % (4/47) of the total variants are novel and not
present in public databases (accessed on June 11th,
2015). All of the novel singleton variants located on
LRRK2, p.D1887N and p.S885C, and GBA, p.T336S
genes are present exclusively in LOPD patients (Table 3).
The PINK1 p.R147C, variant was found in one control
individual but was not present in public datasets.
Copy number analysis
We observed a single structural genomic variant in a 70-
year-old man with a family history of PD (1/126; 0.8 %;
Fig. 1). B allele frequency and log R ratio indicate that
this variant is an intra-chromosomal duplication at the
SNCA locus. We did not identify this duplication, or any
duplication at this locus, in control individuals. No other
exonic rearrangements were observed in any PD patient
in the PARK2, DJ-1 or PINK-1 loci.
Known pathogenic variants
91.5 % (43/47) of the validated variants are reported in
the PD mutation database [22]. Among the previously
known variants, 7 % (3/43) are considered Mendelian
pathogenic mutations for PD (LRRK2 p.G2019S, PINK1
p.R492X and PARK2 p.D53X) (Table 4). Six out of eight
LRRK2 p.G2019S carriers reported PD family history.
Thus, in this sample, 0.6 % (2/352) of the sporadic PD
Table 1 Summary of the sample demographics
Series n Age at onset mean ± SD (range) in years Age at clinical assessment mean ± SD (range) in years Male: Female ratio Caucasian (%)
Total PD 478 61.3 ± 10.6 (40–86) 67.6 ± 10.0 (41–90) 297:181 99
Familial PD 126 59.0 ± 10.9 (40–85) 65.8 ± 11.0 (42–86) 73:53 89
EOPD 83 44.68 ± 2.95 (38–49) 53.4 ± 6.6 (43–71) 51:32 99
Control 337 64.8 ± 10.2 (30–85) 117:220 92
Benitez et al. Molecular Neurodegeneration  (2016) 11:29 Page 2 of 12
Table 2 Summary of the variants found in the European-American case-control sample
Gene AA change Cases (478) MAF Controls (337) MAF p value Clinical interpretation PD mutation database Notes
LRRK2 R50H 0 0 1 0.001 n.s. Unknown Autosomal Dominant
R521G 0 0 1 0.001 n.s. Unknown
R793M 0 0 2 0.003 0.09 Pathogenic nature unclear
S885C 1 0.001 0 0 n.s. Novel
L119P 2 0.002 1 0.001 n.s. Non-pathogenic
P1262A 1 0.001 0 0 n.s. Non-pathogenic
I1371V 2 0.002 0 0 n.s. Pathogenic nature unclear
V1389I 1 0.001 0 0 n.s. Unknown
V1450I 0 0 1 0.001 n.s. Not pathogenic
R1514Q 7 0.007 4 0.006 n.s. Not pathogenic
M1646T 21 0.022 9 0.013 n.s. Not pathogenic/Risk
L1795F 1 0.001 0 0 n.s. Pathogenic nature unclear
D1887N 1 0.001 0 0 n.s. Novel
G2019S 8 0.008 0 0 0.02 Pathogenic
N2081D 17 0.018 15 0.022 n.s. Non-pathogenic
Y2189C 0 0 1 0.001 n.s. Pathogenic nature unclear
A2461V 0 0 1 0.001 n.s. Unknown
Total 62 36
DJ-1 A179T 1 0.0010 0 0 n.s. Pathogenic nature unclear Autosomal Recessive
Total 1 0
PARKIN D53X 1 0.001 0 0 n.s. Pathogenic Autosomal Recessive
R65C 1 0.001 1 0.001 n.s. Pathogenic nature unclear
A82E 1 0.001 1 0.001 n.s. Pathogenic nature unclear
R275W 2 0.002 2 0.003 n.s. Pathogenic nature unclear
E310D 0 0 1 0.001 n.s. Pathogenic nature unclear
R402C 5 0.005 1 0.001 n.s. Pathogenic nature unclear
R402H 0 0 1 0.001 n.s. Unknown
P437L 3 0.003 2 0.003 n.s. Pathogenic nature unclear
Total 13 9
PINK1 R147C 0 0 1 0.001 n.s. Novel Autosomal Recessive
R207Q 1 0.001 0 0 n.s. Unknown
M318L 0 0 1 0.001 n.s. Pathogenic nature unclear
A339S 2 0.002 1 0.001 n.s. Pathogenic nature unclear
N367S 2 0.002 0 0 n.s. Pathogenic nature unclear
G411S 1 0.001 0 0 n.s. Pathogenic nature unclear
R492X 0 0 1 0.001 n.s. Pathogenic
Total 6 4
GBAc R83C 2 0.002 0 0 n.s. Unknown PD GWAS Hit
H294Q 2 0.002 0 0 n.s. Pathogenic
T336S 1 0.001 0 0 n.s. Novel
E365K 19 0.020 11 0.02 n.s. Polymorphism, Risk PD
T408M 17 0.018 0 0 0.0005 Polymorphism
N409S 7 0.007 1 0.001 0.09 Pathogenic, Risk PD
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patients and a 4.8 % (6/126) of the familial PD subjects
carry the LRRK2 p.G2019S mutation. The PARK2
p.D53X mutation heterozygous carrier is an EOPD pa-
tient with a positive family history. The PINK1 p.R492X
heterozygous carrier is an asymptomatic 68-year old in-
dividual with no family history of PD (Table 4).
Of all the previously known variants in all sequenced
genes, 11.6 % (5/43) are located in the GBA gene
(p.H294Q, p.D448H, p.N409S, p.L483P and p.A495P)
and cause Gaucher disease (Table 2). We found that
these variants are overrepresented in the PD patient
sample, but did not reach statistical significance (p = 0.08;
OR = 1.76, 95 % CI = 0.93–3.34). Two GBA variants,
p.T408M and p.E365K, previously described as non-
pathogenic polymorphisms for Gaucher disease, are sig-
nificantly enriched (p = 0.01; OR = 2.35, 95 % CI = 1.19–
4.66) in PD patients (7.5 %; 36/478) compared with
controls (3.2 %; 11/337).
Variants of unclear and unknown pathogenicity
34.9 % (15/43) of the variants located on LRRK2 (four
variants), PARK2 (six variants), PINK1 (4 variants) and
PARK7 (one variant) have been reported previously and
their pathogenicity is unclear (Table 2). Although the cu-
mulative frequency of these variants is higher in PD pa-
tients (4.4 %) compared to controls (3.8 %), this
difference is not statistically significant (p = 0.7; OR =
1.14, 95 % CI = 0.56–2.32), suggesting that either most
of these variants are very unlikely to be true risk fac-
tors for PD or our sample size is not large enough to
detect such differences.
There are 10 variants (21.3 %) with an unknown role
in PD. In this cohort, 1.2 % of PD patients and 1.8 %
of controls were found to carry one of these variants
(p = 0.5; OR = 0.70, 95 % CI = 0.22–2.19).
The non-pathogenic variants, constituting 16.3 % (7/43)
of the variants, were found in a similar proportion of PD pa-
tients (10 %) and controls (9.2 %) (p= 0.68; OR= 1.10, 95 %
CI = 0.68–1.77), supporting their role as non-pathogenic.
Single-variant analysis
The minor allele of GBA p.T408M (p = 4.9 × 10−4) is asso-
ciated with increased PD risk after multiple-testing correc-
tion (Table 2). The GBA p.T408M variant is present in 3.5
% (17/478) of the total number of PD cases and in none of
the control group (Table 2). In addition, we found a nom-
inal association with LRRK2 p.G2019S (p = 0.02) (Table 2).
Using publicly available data from the exome variant ser-
ver (EVS, European American) and Exome Aggregation
Consortium (ExAc, European non-Finish) as controls, the
variants p.T408M (p = 9.0 × 10−4; p = 1.0 × 10−2), p.L483P
(p < 1.0 × 10−4; not found in ExAc), p.R83C (p = 1.0 × 10−2;
p = 1.0 × 10−4), p.N409S (p = 2.0 × 10−2; p = 6.0 × 10−2),
p.H294Q (p = 4.0 × 10−2; p = 1.0 × 10−2) and p.E365K
(p = 4.0 × 10−2; p = 2.0 × 10−2) in the GBA gene,
p.G2019S (p < 1.0 × 10−4; p < 1.0 × 10−4) and
Table 2 Summary of the variants found in the European-American case-control sample (Continued)
E427K 1 0.001 0 0 n.s. Unknown
D448H 1 0.001 1 0.001 n.s. Pathogenica
L483P 7 0.007 2 0.003 n.s. Pathogenica, Risk PD
A495P 17 0.018 10 0.015 n.s. Pathogenicb
Total 74 25 0.001
MAPT A152T 4 0.004 0 0 0.09 Risk AD, FTD PD GWAS Hit
S427F 0 0 2 0.003 0.09 Unknown
A495T 0 0 1 0.001 n.s. Non-pathogenic
A556T 1 0.001 0 0 n.s. Unknown
Total 5 3
Gene: official Symbol provide by HGNC; AA Change: amino acid change resulting from the observed variant; MAF: Minor allele frequency; Clinical Interpretation:
Clinical interpretation is based on PD mutation database [22] and published papers. aGBA variants found in pseudo gene. b Variant also known as p.A485P c
Amino acid designations are based on the primary GBA translation product, including the 39-residue signal peptide
Table 3 Summary of the individuals with novel variants in PD genes
Gene AA Location (Chr:bp) ID Ethnicity AAO PD FAM HISTORY Gender Dementia MMSE
PINK1 R147C 1:20964386 1 Caucasian NA NO F NA NA
LRRK2 S885C 12:40681305 2 Caucasian 67 NO F Yes 28
LRRK2 D1887N 12:40722164 3 Caucasian 55 NO M No 30
GBA T336S 1:155206254 4 Caucasian 62 NO F Possible 27
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p.M1646T (not found in EVS; p = 3.0 × 10−2) in the
LRRK2 gene and PINK1 p.N367S (Not found in EVS;
p = 1.0 × 10−4) all achieved statistical significance in
at least one of the control populations studied
(Table 5).
The MAPT p.A152T variant has been associated with
other neurodegenerative diseases including AD and
frontotemporal dementia (FTD) [23]. In our study, the
MAPT p.A152T variant occurs in 0.8 % (4/478) of PD
cases but in none of the controls (0/337, p = 0.09).
Fig. 1 SNCA duplication. The lower panel shows genotyping data from PD patient, generated using NeuroXchip. Shown is B Allele frequency for
each single-nucleotide polymorphism (SNP) assayed, in which a value of 0 indicates a homozygous A/A genotype, a value of 1 indicates
a homozygous B/B genotype, and a value of 0.5 represents a heterozygous A/B genotype. The highlighted region (pink) delimits the duplicated
segment; within this region are a lack of heterozygous calls and clusters of points at a B allele frequency of ∼ 0.33 and ∼ 0.66, which, coupled with an
increased log R ratio (upper panel), are indicative of A/A/B and A/B/B genotype calls, respectively. Figure plotted using R
Table 4 Summary of the individuals with pathogenic mutations in PD genes
Gene AA rs# ID Ethnicity AAO PD FAM HISTORY Gender Dementia MMSE
LRRK2 G2019S rs34637584 1 Caucasian 42 YES M No 30
2 Caucasian 62 YES F No 30
3 Caucasian 63 YES M No 30
4 Caucasian 68 YES M Yes 16
5 Caucasian 70 YES M No 30
6 Caucasian 77 NO M Yes 25
7 Caucasian 51 YES F Possible 23
8 Caucasian 59 NO F No 29
PARK2 D53Stop 6:162864360 9 Caucasian 50 YES M Possible 28
PINK1 R492X rs34208370 10 Caucasian NA NO M Possible 24
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Gene-burden analyses
To determine whether rare variants in the LRRK2,
DJ1, PARK2, PINK1, GBA or MAPT genes contribute
collectively to PD risk, we performed a gene-burden
association test using the optimal SNP-set sequence
kernel association test (SKAT-O) [24]. Gene-based as-
sociation testing achieved significance for GBA
(PSKAT-O = 7.0 × 10−4; OR = 2.28 (1.41–3.68). Import-
antly, the most commonly reported GBA risk variants
(p.N409S and p.L483P) occur in 2.9 % (14/478) of the PD
cases and in 0.9 % (3/337) of the controls (p = 0.05;
OR = 3.35, 95 % CI = 0.95–11.8). When we exclude
p.N409S and p.L483P from the analysis, the role of
GBA in PD risk remains significant (p = 4.9 × 10−3;
OR = 2.04, 95 % CI = 1.24–3.37), suggesting that add-
itional variants in this gene also increase risk for PD.
When we exclude p.T408M from the analysis, the risk of
PD conferred by GBA variants is not significant (p = 0.39),
which suggests that p.T408M may be the primary driver
of the association with PD risk. These findings highlight
the importance and necessity to sequence the entire GBA
gene as opposed to genotyping only known risk variants
for PD.
We also found a significant enrichment of coding
variants in the LRRK2 gene in PD cases compared to
controls (p = 0.01, OR = 1.86, 95 % CI = 1.14-3.02)
(Table 6), which suggests that there are other risk
variants in the LRRK2 gene in addition to the known
pathogenic p.G2019S mutation.
No significance was found for the MATP2, PARKIN,
PINK1 and DJ-1 genes
Effect on age at onset (AAO) of PD
GBA variant carriers tend to exhibit an earlier AAO than
non-carriers [25]. Thus, we tested whether GBA variants
affect AAO; we found that GBA variants carriers have a
earlier AAO than non-carriers (54 years. vs. 62 years.;
p < 0.0001) (Fig. 2a). Interestingly, when restricted to
carriers and non-carriers of p.N408M using the same
model, carriers had a 5.0-year-earlier onset than non-
carriers (57 years. vs. 62 years.; p = 0.006) (Fig. 2b).
Discussion
Disease-causing variants in the SNCA, LRRK2, PARKIN,
PINK1 and DJ-1 genes have been found in familial early
onset forms of PD [18]. In this study, we systematically
screened for rare variants and pathogenic mutations in
the SNCA, LRRK2, PARK2, PINK1, PARK7, MAPT and
GBA genes in a series of well-characterized PD case-
control samples. A total of 47 low-frequency and rare
non-synonymous coding variants were validated.
Most common pathogenic variants in this cohort
Nine individuals (1.9 %) of the total sample of PD pa-
tients carry a known pathogenic mutation in two
Mendelian genes, LRRK2 p.G2019S and PARK2 p.D53X.
Among patients with a family history of PD, 5.6 %
(7/126) carry a known pathogenic mutation. In this
cohort, we found that among the sequenced genes,
the LRRK2 gene was enriched with multiple variants,
accounting for 36.2 % of all the validated variants.
The LRRK2 p.G2019S mutation is significantly associated
with risk of PD and occurs in 1.7 % of PD patients.
Table 5 Frequency of validated variants in public databases
Gene AA change MAF PD patients EVS MAF p value OR (IC 95 %) ExAC MAF p value OR (IC 95 %)
LRRK2 G2019S 0.008 0.0006 <0.0001 12.67 (4.0–40.2) 0.00063 <0.0001 13.4 (6.2–28.6)
M1646T 0.022 0.0154 n.s. 0.01424 0.03 1.58 (1.02–2.45)
PINK1 N367S 0.002 Not found 0.00002 0.0001 139.6 (12.6–1541)
GBA H294Q 0.002 0.0003 0.04 6.0 (1.0–35.99) 0.0004 0.01 5.82 (1.37–24.7)
R83C 0.002 0.0001 0.01 18.02 (1.63–199) 7.5086E-05 0.0001 27.9 (5.4–144)
N409S 0.007 0.0028 0.02 2.63 (1.13–6.13) 3.6300E-03 0.06 2.03 (0.95–4.31)
L483P 0.007 0.0005 <0.0001 15.85 (4.63–54.24) Not found
T408M 0.018 0.0072 0.0009 2.49 (1.45–4.28) 0.010 0.01 1.85 (1.14–3.01)
E365K 0.020 0.0121 0.04 1.65 (1.01–2.71) 0.012 0.02 1.69 (1.06–2.67)
MAPT A152T 0.004 0.0027 0.4 1.56 (0.54–4.54) 0.002 0.07 2.5 (0.92–6.82)
Table 6 Gene-based analyses for Mendelian and GWAS PD genes
Gene cMAF PD cases cMAF controls P OR
GBA 0.084 0.034 0.0007 2.28 (1.41–3.68)
LRRK2 0.069 0.034 0.01 1.86 (1.14–3.02)
DJ-1 0.001 0 0.64 2.1 (0.08–52.1)
PARKIN 0.014 0.012 0.96 1.01 (0.43–2.40)
PINK1 0.006 0.005 0.93 1.05 (0.29–3.77)
MAPT 0.005 0.004 0.82 1.17 (0.27–4.95)
Results of SKAT-O analyses including all the validated coding variants were
presented. cMAF = cummulative MAF
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Interestingly, mutation carriers were clinically indistin-
guishable from idiopathic PD, which support the evidence
for involvement of this gene in late-onset sporadic PD. A
recent meta-analysis reported that the mean frequency of
the LRRK2 p. G2019S mutation in sporadic PD patients
among studies in the U.S. is 0.4 % [26]. Meanwhile, an-
other international multi-center study reports only 49 of
8371 (0.6 %) PD patients of European and Asian origin
carry the LRRK2 p. G2019S mutation [17]. Both frequen-
cies are similar to the frequency reported here of 0.6 % (2/
352) in sporadic PD patients. Our gene-based analysis
found a significant association with the LRRK2 gene,
which suggests that there are additional risk variants in
LRRK2 affecting PD risk.
We also detected a SNCA locus duplication in a 70-
year-old man with a family history of PD (1/126; 0.8 %;
Fig. 1) and a 3-year history of parkinsonism. This PD pa-
tient exhibited clinical features indistinguishable from
idiopathic PD. As expected, we found no coding muta-
tions in the SNCA gene in this cohort. Point mutations
in the SNCA gene are extremely rare and have been
identified mostly in familial and EOPD [18]. The most
common variation found in the SNCA gene are copy
number variations (CNVs). SNCA duplications are not
fully penetrant and are associated with variable clinical
features, ranging from early-onset with dementia and
psychiatric features to late-onset sporadic [27].
A recent report examining rare variants in the main
Mendelian PD genes in a small case–control sample
consisting of 249 cases and 145 controls of European
origin (Spanish) found an enrichment of rare functional
variants in PD cases [20]. They reported that up to 3.6 %
of patients with sporadic PD are carriers of known
pathogenic mutations in different Mendelian genes. The
difference in the frequency of pathogenic mutations re-
ported here (1.9 %) and that reported by Spataro (3.6 %)
[20] is likely due to differences in methodology (exome
sequencing data vs pooled-targeted sequencing) and to
the different genetic background of the samples (Spanish
vs North American).
Most common risk variants in this cohort
Heterozygous mutations in the GBA gene can be consid-
ered as low penetrance variants with autosomal domin-
ant inheritance for PD [28]. In this study, fifty-three (11
%) of the PD patients and fifteen (4.5 %) controls
carry heterozygous variants in the GBA gene (p = 1.0
× 10−3; OR = 2.17, 95 % CI = 1.36–3.46), which indi-
cate that GBA coding variants increase risk for PD in
this cohort. We also have demonstrated that those
patients with PD carrying a GBA variant experience a
disease onset 6 years earlier than patients without GBA
variants. Interestingly, GBA variants mainly affect AAO of
LOPD patients. Two GBA variants (p.N409S and p.L483P)
have consistently been reported to be associated with in-
creased PD risk in both, Ashkenazi Jewish and non-
Ashkenazi populations [29]. Here, the p.N409S (MAF =
0.007) and p.L483P (MAF = 0.007) variants, are present
in 2.9 % (14/478) of PD patients and 0.9 % (3/337) of
controls. These allelic frequencies agree with previous
reports [29]. We found that both variants are over-
represented in PD cases compared to controls, but they
only reached statistical significance after including a larger
control sample from publicly available databases. In
addition, we report for the first time, an association be-
tween PD risk and the GBA variant p.T408M (MAF:
0.018). p.T408M is considered a polymorphism because it
has been found in control populations [25, 30]. In this
dataset, the GBA p.T408M variant drives the gene-based
association with risk for PD. In the largest Non-Ashkenazi
case–control sample studied to date, the GBA p.T408M
variant was not significantly associated with PD [29]. This
discrepancy could be explained by the heterogeneity of
populations included in that study as it was enriched with
individuals from populations in which the p.T408M vari-
ant is absent or very rare. The p.E365K allele is a
Fig. 2 a. Cumulative incidence rates of PD among carriers and non-carriers of all GBA variants. b. Cumulative incidence rates of PD among carriers
and non-carriers of the p.N408M variant. Survival fractions were calculated using the Kaplan-Meier method and significant differences were calcu-
lated by Log-rank test
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hypomorphic variant (42.7 % of wild type activity) [31]
often found in cis or trans with other Gaucher-
causing non-synonymous mutations [32], exhibiting a
frequency that is similar in controls and Gaucher pa-
tients [33]. We found that p.E365K achieves nominal sig-
nificance (p = 0.02; OR = 1.69, 95 % CI = 1.06–2.67)
after including controls from public databases. Inter-
estingly, the OR found here is similar to those re-
ported previously [33, 34]. Both p.T408M and
p.E365K have been described as “mild” mutations or
modifier alleles. In our study, we did not observe a
“second” mutation that occurred with either p.T408M
or p.E365K, which suggests a second hit may exist as
an interacting factor, similar to those described in a
traditionally considered non-pathogenic variant in AD
[35]. Interestingly, we found seven PD patients carry-
ing PD risk variants in two of all screened genes, fur-
ther suggesting a double-hit mechanism impacting the
risk for PD (Table 7), as reported by the presence of
variants in the LRRK2 and GBA genes in PD patients
[36].
We also found that the MAPT p.A152T variant occurs
in 0.8 % (4/478) of PD cases but in none of the controls
(0/337, p = 0.09). It is possible that the MAPT p.A152T
variant increases PD risk, but this association needs
further confirmation in additional series.
Among the eight variants validated in PARK2, we
found a stop-codon, p.D53X, in an EOPD (early onset
PD) patient with a family history of PD. We also found
one control individual carried the PINK1 (p.R492X) vari-
ant. We validated just a single variant DJ-1, p. A179T in
a 56 year old PD patient with no family history of PD.
All of these variants in recessive genes were found a het-
erozygous manner. Truly causative variants in PARK2,
PINK1 or DJ-1 are present in a homozygous or heterozy-
gous compound manner, but we cannot exclude the
possible role of heterozygous variants on risk of spor-
adic PD. It is important to highlight that the most
common pathogenic mutations in these genes are
exon rearrangements or copy number variations. We did
not detect exonic rearrangements in these genes in our
cohort. The high proportion (83 %) of LOPD and sporadic
cases (74 %) in our sample may explain the low number of
validated variants found in the recessive genes.
Novel variants
We uncovered four novel variants (LRRK2, p.D1887N
and p.S885C), (PINK1, p.R147C), and (GBA, p.T336S) in
0.8 % of PD cases. LRRK2, p.D1887N is located in the
kinase domain and could play a functional role. The
rareness of and the impossibility to expand the
segregation studies with these variants to additional fam-
ily members make its clinical interpretation challenging.
However, finding novel variants in sporadic late onset
PD suggests that it is possible to uncover such variants
in genes linked to Mendelian PD or even in PD cases
with an unclear pattern of inheritance. This is supported
by our gene-based analysis, which demonstrates that
additional untested variants in the GBA and LRRK2
genes contribute to the role of these genes in PD risk.
Conclusions
In summary, our results confirm the strong effect of
GBA and LRRK2 on sporadic PD risk. However, our
gene-based analyses demonstrates that non-synonymous
GBA variants can have a greater impact on PD risk than
LRRK2. In this cohort, the more common pathogenic
mutations are located in the LRRK2 gene. Multiple GBA
gene variants confer the highest risk for PD in our sam-
ple. We report novel interactions between variants in
the GBA and LRRK2 genes as double hits affecting PD
patients with no family history of PD. Our results also
suggest that novel and untested variants in the GBA and
LRRK2 genes influence PD risk. This has important im-
plications on the genetic information provided to pa-
tients and families and potential new therapeutic
Table 7 Individuals carrying two rare variants
Individual Ethnicity AAO PD FAM HISTORY Gender Age at draw rs# Variant in GBA rs# Second Hit Both genes
PD Patient Caucasian 56 NO F 66 rs71653622 A179T rs2230288 E365K GBA and PARK7
Control Caucasian NA NO F 65 rs421016 L483P rs1064651 D448H GBA and GBA
PD Patient Caucasian 46 NO F 57 rs76763715 N409S rs75548401 T408M GBA and GBA
PD Patient Caucasian 63 NO M 77 rs1141812 R83C rs33995883 N2081D GBA and LRRK2
PD Patient Caucasian 82 NO M 87 rs368060 A495P rs33995463 L119P GBA and LRRK2
Control Caucasian NA NO M 66 rs421016 L483P rs35658131 Y2189C GBA and LRRK2
PD Patient Caucasian 59 YES F 61 rs76763715 N409S rs33995883 N2081D GBA and LRRK2
PD Patient Caucasian 73 NO M 75 rs76763715 N409S rs33995883 N2081D GBA and LRRK2
Control Caucasian NA NO F 65 rs368060 A495P rs34424986 R275W GBA and PARK2
PD Patient Caucasian 44 NO M 50 rs76763715 N409S rs45478900 G411C GBA and PINK1
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approaches for PD patients. Our findings also strongly
support the role of the lysosomal system as a pathogenic
pathway in PD. Further work is necessary to clarify the
role of specific and very rare variants in these genes on
risk and PD phenotype.
Methods
Ethics statement
The Institutional Review Board (IRB) at the Washington
University School of Medicine in Saint Louis approved
the study. Prior to their participation, written informed
consent was reviewed and obtained from family mem-
bers. The Human Research Protection Office (HRPO)
approval number for our ADRC Genetics Core family
studies is 201104178.
Samples
Samples included 478 PD patients and 337 healthy indi-
viduals from the Washington University in Saint Louis
Movement Disorder Clinic (MO, USA) [15, 21, 37]. All
were examined by experienced movement disorder clini-
cians (J.S.P.). PD diagnosis was established according to
the UK Brain Bank criteria.
Statistical and association analyses
For each variant, allele frequencies were calculated in
cases and controls, and a χ2 test on allelic association
was performed. A p-value of 0.05 was set as nominal sig-
nificance threshold. The multiple-testing correction cut-
off for the single-variant analysis using Bonferroni
correction for 47 tests is 1.0 × 10−3 (0.05/47). We used
Plink (http://pngu.mgh.harvard.edu/~purcell/plink/) to
analyze associations [38]. The gene-based association
was performed using SKAT-O, which utilizes the R
package SKAT [24]. All variants were included in the
model independent of their clinical interpretation. The
influence of the genetic variants on AAO was carried
out using the Kaplan-Meier method and tested for sig-
nificant differences using a log-rank test.
Pooled-DNA sequencing experiment
Pooled-DNA sequencing was performed as described
previously [35, 39, 40]. Briefly, equimolar amounts of in-
dividual DNA samples were pooled together after being
measured using Quant-iT PicoGreen reagent. Two dif-
ferent pools with 100 ng of DNA from 114 and 98
individuals were made. The coding exons and flanking
regions (a minimum of 50 bp each side) were individu-
ally PCR amplified using specific primers and Pfu Ultra
high-fidelity polymerase (Stratagene). An average of 20
diploid genomes (approximately 0.14 ng DNA) per in-
dividual were used as input for a total of 62 PCR re-
actions that covered 46,319 bases from the 7 genes. PCR
products were cleaned using QIAquick PCR purification
kits, quantified using Quant-iT PicoGreen reagent and li-
gated in equimolar amounts using T4 Ligase and T4
Polynucleotide Kinase. After ligation, concatenated PCR
products were randomly sheared by sonication and pre-
pared for sequencing on an Illumina Genome Analyzer
IIx (GAIIx) according to the manufacturer’s specifications.
pCMV6-XL5 amplicon (1908 base pairs) was included as
a negative control. As positive controls, ten different con-
structs (p53 gene) with synthetically engineered mutations
at a relative frequency of one mutated copy per 250
normal copies were amplified and pooled with the
PCR products. Six DNA samples heterozygous for
previously known mutants in MAPT gene were also
included. Single reads (36 bp) were aligned to the hu-
man genome reference assembly build 36.1 (hg18)
using SPLINTER [41]. SPLINTER uses the positive
control to estimate sensitivity and specificity for vari-
ant calling. The wild type: mutant ratio in the positive
control is similar to the relative frequency expected
for a single mutation in one pool (1 chromosome
mutated in 125 samples = 1/250). SPLINTER uses the
negative control (first 900 bp) to model the errors
across the 36-bp Illumina reads and to create an
error model from each sequencing run of the ma-
chine. Based on the error model, SPLINTER calcu-
lates a p-value for the probability that a predicted
variant is a true positive. A p-value at which all mutants in
the positive controls were identified was defined as the
cut-off value for the best sensitivity and specificity. All
mutants included as part of the amplified positive control
vector were found upon achieving >30-fold coverage at
mutated sites (sensitivity = 100 %) and only ∼ 80 sites in
the 1908 bp negative control vector were predicted to
be polymorphic (specificity = ∼95 %). The variants
with a p-value below this cut-off value were consid-
ered for follow-up confirmation.
Genotyping
All rare missense or splice site variants identified by
SPLINTER were validated by directly genotyping all se-
quenced individuals using Sequenom iPLEX or KASPar
genotyping systems as described previously [42–44]. The
validated SNPs were then genotyped in all members of
the series. An average coverage of 30-fold per allele per
pool is the minimum coverage necessary to obtain an
optimal positive predictive value for the SNP-calling
algorithm [41]. The necessary number of lanes to obtain
a minimum of 30-fold coverage per base and sample
were run.
Copy number variation analysis
The B Allele frequency and Log R Ratio were used to
identify genomic deletions and duplications as previously
described [45] using NeuroX chip data [46].
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Bioinformatics
The PD mutation database [22] was used to identify
sequence variants previously found in other studies
of familial PD and to determine whether or not they
are considered to be disease-causative variants. The
EVS (http://evs.gs.washington.edu/EVS/), SeattleSeq An-
notation (http://snp.gs.washington.edu/SeattleSeqAn-
notation137/), The Exome Aggregation Consortium
(ExAC) http://exac.broadinstitute.org/ (June 19, 2015) and
the Ensembl Genome Database (http://useast.ensembl.org/
index.html) were used to annotate the rare variants. Poly-
phen algorithms were used to predict the functional effect
of the identified variants.
Population structure
A PCA was conducted to infer genetic structure of
individuals who have GWAS data available using the
EIGENSTRAT software as previously described [40].
Samples were excluded if not located within the EA
cluster. Individuals who do not have GWAS data avail-
able were included in the study if the self-reported eth-
nicity was non-Hispanic European.
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